None listed
Conditions
Interventions
Medical Device : 1) Number of study subjects: 58 people in total (29 control group, 29 test group)
2) Applicable device: Bye-Vi
3) Interventional treatment: Investigation and application to the nasal
Sponsors
Nanobioimaging
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult men and women between the ages of 19 and 65 2. Patients whose cold symptoms occurred within 48 hours before clinical trial screening 3. Among the 8 cold symptoms*, those who have a total score of 8 or more for the 4 commonly experienced local symptoms: sore throat, cough, sneezing, and runny nose. 4. A person who agrees not to take any medicine related to colds while participating in a clinical trial 5. Those who fully understand the research purpose and procedures and wish to participate in clinical research through voluntary consent * The Jackson Symptom score, developed by Jackson in 1958 and widely used in cold clinical trials, is an indicator of five local symptoms: sore throat, runny nose, stuffy nose, cough, and sneezing, and systemic symptoms such as headache, muscle pain, and chills. For each of the three symptoms, 0=no symptoms, 1=mild (feeling it but not difficult or irritating), 2=moderate (somewhat difficult and irritating), 3-severe (difficult and irritating all the time). Calculated by calculating (1, 18).
Exclusion criteria
Exclusion criteria: 1. People with known photosensitivity or photoallergy 2. Those with a body temperature of 37.5 degrees or higher 3. Those currently suffering from allergic rhinitis, chronic obstructive pulmonary disease (COPD), or severe nasal syndrome. 4. Those with nasal congestion caused by nasal polyps, previous nasal surgery, or symptoms that may affect the score 5. Those with a history of alcoholism, drug abuse, or use of prescription drugs/unsuitable drugs (e.g. birth control pills, systemic steroids, intranasal drugs, antibiotics, etc.) 6. Persons with symptoms of infection other than respiratory tract 7. Pregnant and lactating women, those who test positive for pregnancy on a urine test, and those who are planning to become pregnant during the clinical trial period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total symptom score | — |
Secondary
| Measure | Time frame |
|---|---|
| complete blood cell count with difference count;C-reactive protein, CRP;virus Polymerase Chain Reaction Test | — |
Countries
Korea, Republic of
Contacts
Public ContactSEUNG-ROK KANG
Jeonbuk National University Hospital
Outcome results
None listed